An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, With Emphasis on Unexpected Hormone/Radiation Interactions

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 3, 2007, Pages 646-655

  Lawton, Colleen A ^a   DeSilvio, Michelle ^b   Roach III, Mack ^c   Uhl, Valery ^d   Kirsch, Robert ^e   Seider, Michael ^f   Rotman, Marvin ^g   Jones, Christopher ^h   Asbell, Sucha ⁱ   Valicenti, Richard ^j   Hahn, Stephen ^k   Thomas Jr , Charles R ^l  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Summitt Medical Center   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f AKRON CITY HOSPITAL   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h Radiological Associates of Sacramento Medical Group Inc   (United States)

ⁱ ALBERT EINSTEIN MEDICAL CENTER   (United States)

^j THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^k WAYNE STATE UNIVERSITY   (United States)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

Hormonal therapy; Prostate cancer; Radiotherapy

Indexed keywords

ANTIGENS; BIOLOGICAL ORGANS; HORMONES; ONCOLOGY; RISK ANALYSIS; STATISTICAL METHODS; TUMORS;

NEOADJUVANT HORMONAL THERAPY (NHT); PROSTATE CANCER; RADIATION INTERACTIONS; WHOLE PELVIC RADIOTHERAPY (WPRT);

RADIOTHERAPY;

ANDROGEN; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLEASON SCORE; HORMONAL THERAPY; HORMONE ACTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; RADIATION FIELD; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT;

EID: 34548682063     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.04.003     Document Type: Article

References (24)

1. Pilepich M., Winter K., Lawton C., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
2. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
3. Bolla M., Collette L., Blank L., et al. Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study, a phase III randomized trial). Lancet 360 (2002) 103-108
4. Hanks G.F., Bae K., Porter A., et al. Ten year follow-up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. Proc ASTRO 66 (2006) S13
5. D'Amico A.V., Loffredo M., Renshaw A., et al. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 24 (2006) 4190-4195
6. Denham J.W., Steigler A., Lamb D., et al. Short term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet 6 (2005) 841-850
7. Lavadiere J., Nabid A., DeBedoya L.D., et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171 (2004) 137-140
8. Roach M. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 1923-1924
9. Roach M., Lu J., Pilepich M.V., et al. Predicting long term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47 (2000) 617-627
10. Pilepich MV, Winter K, Roach M, et al. Phase III RTOG trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Presented at the American Society of Clinical Oncology, Los Angeles, CA, May 16-19, 1998.
11. Roach M., Marquez C., Yuo H., et al. Predicting the risk of lymph node involvement using the pre-treatment specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1993) 33-37
12. Roach M., Pickett B., Holland J., et al. The role of the urethrogram during simulation for localized prostate cancer. Int J Radiat Oncol Biol Phys 25 (1993) 299-307
13. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
14. Gaynor J.J., Feuer E.J., Tan C.C., et al. On the use of cause-specific and conditional failure probabilities. J Am Stat Assoc 88 (1993) 400-409
15. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
16. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the RTOG and EORTC. Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
17. Cox J.D., Grignon D.J., Kaplan R.S., et al. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
18. Kestin L.L., Vicini F.A., and Martinex A.A. Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys 53 (2002) 304-315
19. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
20. Fleming T.R., Green S.J., and Harrington D.P. Considerations for monitoring and evaluating treatment effects in clinical trials. Control Clin Trials 5 (1984) 55-66
21. Fleming T.R., Harrington D.P., and O'Brien P.C. Designs for group sequential tests. Control Clin Trials 5 (1984) 348-361
22. Roach M., DeSilvio M., Valicenti R., et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the RTOG 94-13 trial. Int J Radiat Oncol Biol Phys 66 (2006) 647-653
23. Mercader M., Bodner B., Moser M., et al. T-cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci 98 (2001) 14565-14570
24. Zhang L., Conejo-Garcia J., Katsaros D., et al. Intratumoral T-cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2004) 203-213